Lercanidipine hydrochloride, supplied under the designation Lercanidipine Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable, is a crystalline dihydropyridine L-type calcium-channel antagonist with the molecular formula C₃₆H₄₁N₃O₆·HCl and a relative molecular mass of 648.2 g/mol. The material is manufactured under ICH Q7 GMP conditions and is controlled for identity, assay, related substances, residual solvents, water content, particle size, and polymorphic form. The product designation is functional rather than monograph-defined: no universal pharmacopoeial model identifier is assigned to lercanidipine hydrochloride, so oral-grade powder, micronized direct-compression grade, and injectable-development grade are typically distinguished by internal item codes and certificate-of-analysis data. Those model codes should not be interchanged without verifying particle size, endotoxin, and bioburden status.

Published biopharmaceutics assessments place lercanidipine hydrochloride in BCS Class II, meaning that its intestinal permeability is relatively high while its aqueous dissolution rate limits absorption. Formulators using the API for tablets, capsules, or granule intermediates therefore prioritize particle size reduction, wetting agent selection, and dissolution-method discrimination. In oral solid dosage forms, the commonly used unit strengths are 10 mg and 20 mg once daily. Other strengths are formulation-dependent and require supportive bioequivalence data under current regulatory guidance.

Pharmacologically, lercanidipine inhibits L-type calcium channels in vascular smooth muscle. In vitro data show that the molecule has a higher n-octanol/water distribution coefficient than many first- and second-generation dihydropyridines, producing slower onset of vasodilation and prolonged residence in membrane-rich compartments. This kinetic behaviour is a differentiating factor when compared with nifedipine, which requires modified-release technology for once-daily use, and with amlodipine, which has a longer plasma elimination half-life. Clinical trial comparisons report a lower incidence of peripheral edema for lercanidipine 10–20 mg once daily than for amlodipine 10 mg once daily in selected hypertensive populations, although direct comparative evidence remains heterogeneous.

How Do Release Specifications Separate Oral-Grade From Injectable-Development Material?

Control of lercanidipine hydrochloride for solid oral products is based on pharmacopoeial general methods and ICH Q6A decision trees. Injectable development-grade material adds bioburden, endotoxin, and particulate controls that are not routinely applied to tablet or capsule intermediates. The table below lists representative acceptance expectations; registered limits must be read from the active substance dossier or supplier certificate of analysis.

For oral solid dosage forms, residual solvents are controlled by headspace gas chromatography according to Ph. Eur. 2.4.24 or USP <467> and classified under ICH Q3C. Because lercanidipine is a single chemical entity, dissolution and content uniformity are not API release tests; those attributes are applied to the finished tablet or capsule using Ph. Eur. 2.9.3, Ph. Eur. 2.9.6, Ph. Eur. 2.9.40, or USP <711> and USP <905> as appropriate.

Particle size control is a release parameter for oral-grade lercanidipine hydrochloride because dissolution in BCS Class II substances is directly influenced by specific surface area. Laser diffraction methods under Ph. Eur. 2.9.31, USP <429>, or ISO 13320 are used with dry dispersion pressures typically in the range of 0.5–3.0 bar to reduce agglomeration. A conventional oral-grade specification is D90 ≤ 150 µm for granulation or capsule fill, while micronized direct-compression material may be controlled at D90 ≤ 30 µm with D50 ≤ 10 µm. Cohesive fines can consolidate during storage, so particle size should be re-checked after transport and before use to prevent blend uniformity drift.

Wet granulation is not a neutral step for dihydropyridine crystalline materials. Lercanidipine hydrochloride batches intended for granulation should be evaluated by X-ray powder diffraction according to Ph. Eur. 2.9.33 or USP <941> before and after aqueous binder addition, because processing moisture and drying can alter amorphous content and surface crystal habit. If granule drying exceeds 60 °C or continues beyond the endpoint moisture specification, the crystalline form may be retained while chemical degradation increases; the finished granule should be re-assayed for related substances using a stability-indicating HPLC method before compression.

If Injectable Administration Is Required, Aseptic Processing and Solubility Constraints Apply

Injectable development with lercanidipine hydrochloride differs from oral solid-dose manufacturing because the API has low aqueous solubility in the near-neutral pH range. Simple reconstitution in water for injection is therefore not a feasible product configuration. Enabling approaches include buffered cosolvent systems, cyclodextrin complexation, nano-milling, or lipid-based emulsions. Each requires qualification of API particle size, surface charge, and residual solvent profile after processing. Published data for licensed injectable lercanidipine products are limited, so formulation performance cannot be extrapolated from oral bioavailability or tablet dissolution data.

For injectable-grade material, bioburden and endotoxin are release parameters rather than optional tests. The final sterile drug product is typically passed through a 0.22 µm sterilizing-grade filter under aseptic conditions or subjected to a validated terminal sterilization cycle. Terminal sterilization must account for thermal degradation of the dihydropyridine ring. Release testing includes bacterial endotoxin by Ph. Eur. 2.6.14 or USP <85>, sterility by Ph. Eur. 2.6.1 or USP <71>, and subvisible particulate analysis by Ph. Eur. 2.9.19 or USP <788>.

Filter compatibility studies should be conducted with polyether sulfone and polyvinylidene fluoride membranes, because lipophilic APIs can adsorb to polymer surfaces and reduce delivered dose. A terminal moist-heat cycle at 121 °C for 15 min may exceed the degradation threshold for lercanidipine; if related substances increase beyond the shelf-life specification or discoloration occurs, aseptic processing is indicated. Injectable formulations also require compatibility testing with primary packaging, because silicone oil droplets and glass delamination may appear as subvisible particles under USP <788> conditions.

Comparative Physicochemical and Pharmacological Profile of Dihydropyridine Alternatives

Lercanidipine hydrochloride differs from amlodipine besylate, nifedipine, and felodipine in salt form, membrane distribution, plasma half-life, and dosing interval. Amlodipine besylate is a long plasma half-life dihydropyridine with a usual once-daily dose of 5–10 mg; lercanidipine hydrochloride is administered once daily at 10–20 mg. Nifedipine immediate-release formulations require multiple daily dosing and may induce reflex sympathetic activation unless modified-release technology is used. Felodipine occupies an intermediate lipophilicity range and requires extended-release tablets for once-daily administration.

Pharmacopoeial and peer-reviewed literature data show that lercanidipine has a high membrane partition coefficient, with a plasma elimination half-life commonly reported in the range of 8–10 h, compared with 35–50 h for amlodipine and 2–5 h for immediate-release nifedipine. Despite its shorter plasma half-life, lercanidipine maintains a 24 h antihypertensive effect because of prolonged residence in vascular smooth-muscle membrane compartments. That membrane-partitioning characteristic is the technical basis for the lower incidence of peripheral edema reported with lercanidipine in some comparative hypertension studies. These differences are clinically relevant because lercanidipine is not dose-equivalent to amlodipine or nifedipine; substitution among these agents requires retitration under clinical supervision.

The salt form also differs: lercanidipine is supplied as the hydrochloride, while amlodipine is commonly supplied as amlodipine besylate. This difference can affect solubility, stability in excipient matrices, and analytical detection. High-performance liquid chromatographic methods for assay and impurities must be specific for the hydrochloride salt and must resolve process-related dihydropyridine degradants. Compendial thin-layer chromatographic identification is not sufficient for release; stability-indicating HPLC or UHPLC methods are required under ICH Q2(R1) validation.

Direct compression of lercanidipine hydrochloride at a 10 mg dose strength often requires the API to be milled to a D90 below 150 µm and preferably below 30 µm when content uniformity in low-weight tablet cores is critical. Micronized material exhibits higher specific surface area and may require the addition of colloidal silicon dioxide at 0.5–1.0% w/w or a pre-blend step to control flowability through the tablet press feed frame. In rotary tablet compression, blending beyond the homogeneity endpoint can increase segregation risk because lercanidipine hydrochloride has cohesive surface properties. Mixing studies should define an optimum window rather than relying on a default blending time.

Quality system documentation for lercanidipine pharma-grade API should include an ICH Q7 batch record, an ICH Q1A stability commitment, an ICH Q3A impurity discussion, and an ICH Q3C residual solvent declaration. Storage in tight containers protected from light under conditions such as 25 °C/60% RH, with excursions defined by ICH Q1A and Zone II requirements, is common for oral-grade material. The API should not be commingled with other dihydropyridines in multi-use dispensing areas without validated cleaning procedures, because cross-contamination from antihypertensive agents presents an operational risk. Published data for the combined oral-plus-injectable configuration specified in the product designation are limited; each intended dosage form must be developed and validated separately against the registered specification and the relevant pharmacopoeial standard.